{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T23:54:42Z","timestamp":1771026882004,"version":"3.50.1"},"reference-count":54,"publisher":"BMJ","issue":"12","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,11,28]]},"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Evaluate tofacitinib efficacy, safety and persistence by sex in rheumatoid arthritis (RA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Post hoc analyses using data from phase III placebo-controlled randomised controlled trials (ORAL Scan, ORAL Sync and ORAL Standard).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>ORAL Scan, ORAL Sync and ORAL Standard were global, multicentre trials conducted across 111, 114 and 115 sites, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>The trials enrolled adults with active RA and prior inadequate response to methotrexate (ORAL Scan\/ORAL Standard) or \u22651 conventional synthetic or biologic disease-modifying antirheumatic drug (ORAL Sync). Post hoc analyses included 2265 patients (1870 female and 395 male).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Patients received tofacitinib 5 mg or 10\u2009mg two times a day, adalimumab or placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>\n                      Efficacy outcomes to month 12 included American College of Rheumatology (ACR)20, 50 and 70 responses, Disease Activity Score in 28 joints (DAS28) (erythrocyte sedimentation rate (ESR))-defined low disease activity (LDA) and remission, DAS28 (C reactive protein (CRP)) \u22643.2\u2009and &lt;2.6 and normative thresholds for Health Assessment Questionnaire-Disability Index (HAQ-DI) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F). Regression analyses included exploration of possible non-linearity in the relationship between age and treatment response in males and females. Safety was evaluated at month 24. Additionally, Kaplan-Meier survival analysis of two open-label, long-term extension studies (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00661661\">NCT00661661<\/jats:ext-link>\n                      and ORAL Sequel) assessed time to discontinuation of tofacitinib treatment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, female patients had similar DAS28(CRP and ESR), slightly higher HAQ-DI and lower FACIT-F scores versus male patients (n=395). ORs for active treatments (tofacitinib and adalimumab) versus placebo were generally &gt;1 for ACR20, 50 and 70 responses, DAS28(CRP) \u22643.2\u2009and &lt;2.6, DAS28(ESR) LDA and remission and proportions of patients reporting FACIT-F scores \u2265normative values and trends towards numerically higher ORs in males versus females were observed. Sex differences were not consistently observed for HAQ-DI normative threshold ORs and, for most outcomes, when comparing responses within active treatment groups by sex. Polynomial modelling suggested age did not impact treatment response differences. Safety and persistence were similar across sexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In post hoc analyses, tofacitinib was efficacious across both sexes, with higher responses in males observed particularly for more stringent composite endpoints and patient-reported outcomes. Findings are generally consistent with studies of other advanced RA therapies. Safety and persistence were similar across sexes. Interpretation is limited by the small proportion of male patients (&lt;20%) and baseline differences between sexes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00847613\">NCT00847613<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00856544\">NCT00856544<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00853385\">NCT00853385<\/jats:ext-link>\n                      ,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00661661\">NCT00661661<\/jats:ext-link>\n                      and\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT00413699\">NCT00413699<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-082366","type":"journal-article","created":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T06:10:16Z","timestamp":1766643016000},"page":"e082366","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Sex differences in the efficacy, safety and persistence of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of phase III and long-term extension trials"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct00661661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00661661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00847613","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00856544","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00853385","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00661661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00661661","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00413699","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4978-4072","authenticated-orcid":false,"given":"Vibeke","family":"Strand","sequence":"first","affiliation":[{"name":"Division of Immunology\/Rheumatology, Stanford University, Palo Alto, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1681-491X","authenticated-orcid":false,"given":"Hendrik","family":"Schulze-Koops","sequence":"additional","affiliation":[{"name":"Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samar","family":"Al-Emadi","sequence":"additional","affiliation":[{"name":"Hamad Medical Corporation, Doha, Qatar"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra D","family":"Kinch","sequence":"additional","affiliation":[{"name":"Pfizer Canada ULC, Kirkland, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Germino","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol A","family":"Connell","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Groton, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo","family":"Mysler","sequence":"additional","affiliation":[{"name":"Rheumatology, Organizaci\u00f3n M\u00e9dica de Investigaci\u00f3n, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"2026010703495426000_15.12.e082366.1","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-15-44","article-title":"Changes and sex differences in patient reported outcomes in rheumatoid factor positive RA-results from a community based study","volume":"15","author":"Hekmat","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"2026010703495426000_15.12.e082366.2","doi-asserted-by":"crossref","DOI":"10.1186\/ar2591","article-title":"Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study","volume":"11","author":"Sokka","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"2026010703495426000_15.12.e082366.3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/acr.23873","article-title":"Sex Differences in the Achievement of Remission and Low Disease Activity in Rheumatoid Arthritis","volume":"72","author":"Maynard","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010703495426000_15.12.e082366.4","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171176"},{"key":"2026010703495426000_15.12.e082366.5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110548"},{"key":"2026010703495426000_15.12.e082366.6","first-page":"467","article-title":"Factors Predicting 2 Years of Remission and Low Disease Activity in Rheumatoid Arthritis Patients Treated with TNF-inhibitors","volume":"19","author":"Conigliaro","year":"2017","journal-title":"Isr Med Assoc J"},{"key":"2026010703495426000_15.12.e082366.7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0266816","article-title":"Sex difference in disease burden of inflammatory arthritis patients treated with tumor necrosis factor inhibitors as part of standard care","volume":"17","author":"Michelsen","year":"2022","journal-title":"PLoS One"},{"key":"2026010703495426000_15.12.e082366.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150007"},{"key":"2026010703495426000_15.12.e082366.9","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1151-6","article-title":"Patient global assessment in measuring disease activity in rheumatoid arthritis: a review of the literature","volume":"18","author":"Nikiphorou","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026010703495426000_15.12.e082366.10","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12016-017-8631-6","article-title":"Sex, Symptom Severity, and Quality of Life in Rheumatology","volume":"56","author":"Krasselt","year":"2019","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026010703495426000_15.12.e082366.11","first-page":"1620","article-title":"Onset of symptoms of rheumatoid arthritis in relation to age, sex and menopausal transition","volume":"17","author":"Goemaere","year":"1990","journal-title":"J Rheumatol"},{"key":"2026010703495426000_15.12.e082366.12","first-page":"1809","article-title":"Influence of sex, age, and menopausal state on the course of early rheumatoid arthritis","volume":"28","author":"Kuiper","year":"2001","journal-title":"J Rheumatol"},{"key":"2026010703495426000_15.12.e082366.13","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1007\/s10067-022-06307-8","article-title":"Predictors of remission in rheumatoid arthritis patients treated with biologics: a systematic review and meta-analysis","volume":"41","author":"Khader","year":"2022","journal-title":"Clin Rheumatol"},{"key":"2026010703495426000_15.12.e082366.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.094730"},{"key":"2026010703495426000_15.12.e082366.15","first-page":"390","article-title":"Efficacy and safety of tofacitinib in older and younger patients with rheumatoid arthritis","volume":"35","author":"Curtis","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2026010703495426000_15.12.e082366.16","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaut.2019.02.004","article-title":"RA and the microbiome: do host genetic factors provide the link?","volume":"99","author":"Wells","year":"2019","journal-title":"J Autoimmun"},{"key":"2026010703495426000_15.12.e082366.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-eular.2398"},{"key":"2026010703495426000_15.12.e082366.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.37816"},{"key":"2026010703495426000_15.12.e082366.19","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-159-4-201308200-00006"},{"key":"2026010703495426000_15.12.e082366.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1112072"},{"key":"2026010703495426000_15.12.e082366.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-0932-2","article-title":"Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study","volume":"18","author":"Yamanaka","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026010703495426000_15.12.e082366.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.130683"},{"key":"2026010703495426000_15.12.e082366.23","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026010703495426000_15.12.e082366.24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026010703495426000_15.12.e082366.25","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110392"},{"key":"2026010703495426000_15.12.e082366.26","first-page":"557","article-title":"Minimum important difference between patients with rheumatoid arthritis: the patient\u2019s perspective","volume":"20","author":"Wells","year":"1993","journal-title":"J Rheumatol"},{"key":"2026010703495426000_15.12.e082366.27","doi-asserted-by":"publisher","DOI":"10.1002\/art.20048"},{"key":"2026010703495426000_15.12.e082366.28","first-page":"811","article-title":"Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"key":"2026010703495426000_15.12.e082366.29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","article-title":"General Population Norms for the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Scale","volume":"21","author":"Montan","year":"2018","journal-title":"Value Health"},{"key":"2026010703495426000_15.12.e082366.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.02.010"},{"key":"2026010703495426000_15.12.e082366.31","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-7-12","article-title":"Sex differences in rheumatoid arthritis: more than meets the eye","volume":"7","author":"van Vollenhoven","year":"2009","journal-title":"BMC Med"},{"key":"2026010703495426000_15.12.e082366.32","doi-asserted-by":"publisher","DOI":"10.1007\/s11999-010-1759-9"},{"key":"2026010703495426000_15.12.e082366.33","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.37765\/ajmc.2020.88544","article-title":"Rheumatoid arthritis medication adherence in a health system specialty pharmacy","volume":"26","author":"Berger","year":"2020","journal-title":"Am J Manag Care"},{"key":"2026010703495426000_15.12.e082366.34","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-15-368","article-title":"How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis","volume":"15","author":"Siemons","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"2026010703495426000_15.12.e082366.35","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002718","article-title":"Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension","volume":"9","author":"Eder","year":"2023","journal-title":"RMD Open"},{"key":"2026010703495426000_15.12.e082366.36","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S134745"},{"key":"2026010703495426000_15.12.e082366.37","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2019.00160","article-title":"Does Sex\/Gender Play a Role in Placebo and Nocebo Effects? Conflicting Evidence From Clinical Trials and Experimental Studies","volume":"13","author":"Enck","year":"2019","journal-title":"Front Neurosci"},{"key":"2026010703495426000_15.12.e082366.38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/RHU.0000000000000786","article-title":"Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety","volume":"25","author":"Bird","year":"2019","journal-title":"J Clin Rheumatol"},{"key":"2026010703495426000_15.12.e082366.39","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-017-0073-3"},{"key":"2026010703495426000_15.12.e082366.40","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev442"},{"key":"2026010703495426000_15.12.e082366.41","first-page":"592","article-title":"Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis","volume":"69","author":"Strand","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2026010703495426000_15.12.e082366.42","first-page":"848","article-title":"Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study","volume":"38","author":"Strand","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"2026010703495426000_15.12.e082366.43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080724"},{"key":"2026010703495426000_15.12.e082366.44","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000041","article-title":"Fatigue in rheumatoid arthritis; a persistent problem: a large longitudinal study","volume":"1","author":"van Steenbergen","year":"2015","journal-title":"RMD Open"},{"key":"2026010703495426000_15.12.e082366.45","doi-asserted-by":"publisher","DOI":"10.1002\/art.24430"},{"key":"2026010703495426000_15.12.e082366.46","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0950-3579(05)80344-9","article-title":"The effects of gender and sex hormones on outcome in rheumatoid arthritis","volume":"6","author":"Da Silva","year":"1992","journal-title":"Baillieres Clin Rheumatol"},{"key":"2026010703495426000_15.12.e082366.47","article-title":"Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care databases","volume":"55","author":"Souto","year":"2016","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2026010703495426000_15.12.e082366.48","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.2147\/DDDT.S97088","article-title":"Gender differences in the adverse events\u2019 profile registered in seven observational studies of a wide gender-medicine (MetaGeM) project: the MetaGeM safety analysis","volume":"10","author":"Colombo","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"2026010703495426000_15.12.e082366.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"2026010703495426000_15.12.e082366.50","doi-asserted-by":"crossref","unstructured":"Charles-Schoeman C , Buch M , Dougados M , et al . Risk factors for major adverse cardiovascular events in patients aged \u2265 50 years with RA and \u2265 1 additional cardiovascular risk factor: results from a Phase 3b\/4 randomized safety study of tofacitinib vs TNF inhibitors. Arthritis Rheumatol 2021;0958.","DOI":"10.1136\/annrheumdis-2022-eular.1016"},{"key":"2026010703495426000_15.12.e082366.51","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard-2022-222405","article-title":"Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial","volume":"81","author":"Balanescu","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"2026010703495426000_15.12.e082366.52","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.14312"},{"key":"2026010703495426000_15.12.e082366.53","doi-asserted-by":"publisher","DOI":"10.1016\/j.annepidem.2005.12.002"},{"key":"2026010703495426000_15.12.e082366.54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204920"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-082366","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T11:54:24Z","timestamp":1767786864000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-082366"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":54,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12,24]]},"published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1136\/bmjopen-2023-082366"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-082366","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}